The above findings gave us a deeper understanding of the molecular aspects of cancer progression, and provided a great opportunity to improve the therapeutic efficacy against NPC and other cancers with high ANXA2 expression. This evidence concerns the gene ANXA2 and nasopharyngeal carcinoma.